All In Biotech

Drug Trial Radar · NCT03340675

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

Oct 19, 2020

Primary completion

Mar 6, 2024

Study completion Jan 23, 2026

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Vanderbilt University Medical Center
First posted
Nov 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD. Funding Source - FDA OOPD

Conditions

  • Duchenne Muscular Dystrophy Cardiomyopathy
  • Cardiomyopathy, Dilated

Interventions

  • IfetrobanDrug

    Weight based, once daily oral ifetroban

  • PlaceboDrug

    Matching oral placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Baseline through 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Mattel Children's Hospital

    Los Angeles, California

  • Children's National Hospital

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Lurie Children's Hospital

    Chicago, Illinois

  • Riley Children's Hospital

    Indianapolis, Indiana

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Saint. Louis Children's Hospital

    St Louis, Missouri

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Monroe Carrell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.